Callan Family Office’s Teva Pharmaceuticals TEVA Stock Holding History

Callan Family Office’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.72M	Sell	50,826 -12,428	-20%	-$414K	0.03%	434
2026 Q1	$1.91M	Buy	63,254 +22,358	+55%	+$719K	0.04%	370
2025 Q4	$1.28M	Buy	40,896 +18,944	+86%	+$467K	0.03%	471
2025 Q3	$443K	Sell	21,952 -8,239	-27%	-$145K	0.01%	566
2025 Q2	$506K	Buy	+30,191	New	+$487K	0.02%	581
2025 Q1	–	Sell	-9,389	Closed	-$207K	–	640
2024 Q4	$207K	Buy	+9,389	New	+$171K	0.01%	595

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Callan Family Office's TEVA Position: Q2 2026 in Review

Callan Family Office reduced its Teva Pharmaceuticals (TEVA) stake by 20% in Q2 2026, selling an estimated $414K and leaving 50,826 shares worth $1.72M. The position accounts for 0.03% of the portfolio, ranked #434.

Callan Family Office first reported a position in TEVA in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.91M in Q1 2026. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Callan Family Office held 50,826 shares of Teva Pharmaceuticals worth $1.72M as of Q2 2026.
Callan Family Office sold 12,428 Teva Pharmaceuticals shares in Q2 2026, an estimated $414K.
Teva Pharmaceuticals made up 0.03% of Callan Family Office's portfolio in Q2 2026, its #434 holding.
Callan Family Office first reported a position in Teva Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Callan Family Office's Teva Pharmaceuticals position peaked at $1.91M in Q1 2026.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.